Published in Hum Vaccin Immunother on January 01, 2015
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | NCT00351949
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer | NCT00057889
Clinical significance of B7-H6 protein expression in astrocytoma. Onco Targets Ther (2016) 0.77
Systemic therapy in metastatic renal cell carcinoma. World J Urol (2016) 0.77
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017) 0.75
Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Cancer; a biological approach. I. The processes of control. Br Med J (1957) 2.29
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43
What's the difference between CD80 and CD86? Trends Immunol (2003) 1.29
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer (2010) 1.12
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res (2009) 1.12
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther (2012) 0.87
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? Expert Rev Anticancer Ther (2013) 0.78
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Urinary diversion. Urology (2007) 2.65
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51
The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47
Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol (2010) 1.12
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med (2013) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm (2009) 1.10
HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08
Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.07
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med (2011) 1.05
Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol (2012) 1.04
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int (2012) 1.04
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci (2009) 1.02
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res (2006) 1.02
Investigations of urothelial cells seeded on commercially available small intestine submucosa. Eur Urol (2006) 1.01
Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med (2008) 1.01
Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones. BJU Int (2012) 1.01
Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). BJU Int (2011) 1.01
Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol (2009) 1.00
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer (2011) 1.00
A newly designed amplatz sheath decreases intrapelvic irrigation pressure during mini-percutaneous nephrolitholapaxy: an in-vitro pressure-measurement and microscopic study. J Endourol (2007) 1.00
Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur J Immunol (2008) 0.99
Advances in the treatment of testicular cancer. Drugs (2006) 0.99
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (2011) 0.98
Small renal oncocytomas: differentiation with multiphase CT. Eur J Radiol (2010) 0.97
Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int (2012) 0.97
DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin Cancer Res (2013) 0.97
GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int (2012) 0.97
Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep (2006) 0.97
Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int (2009) 0.96
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer (2005) 0.96
Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int (2008) 0.96
Tumorsize dependent detection rate of endorectal MRI of prostate cancer--a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol (2010) 0.95
Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol (2013) 0.94
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci (2013) 0.94
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol (2002) 0.93
Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother (2006) 0.93
Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate (2008) 0.93
Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: a feasibility study and the first clinical results. BJU Int (2008) 0.93